Saturday, July 12, 2008

FDA Update for Healthcare Professionals - July 9, 2008

FDA Approves New Genetic Test for Patients with Breast Cancer (July 8)

The U.S. Food and Drug Administration has approved a novel genetic test for determining whether patients with breast cancer are good candidates for treatment with the drug Herceptin (trastuzumab). The SPOT-Light HER2 CISH kit is a test that measures the number of copies of the HER2 gene in tumor tissue. This gene regulates the growth of cancer cells.

FDA Approves First Generic Risperidone to Treat Psychiatric Conditions (June 30)

The U.S. Food and Drug Administration today approved the first generic versions of Risperdal (risperidone) tablets. Risperdal is an antipsychotic drug used for the treatment of schizophrenia, bipolar disorder, and other psychiatric conditions.

No comments: